Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

October 2024

Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study

MD Open. 2024 Sep 20;10:e004318 doi: 10.1136/rmdopen-2024-004318

Ng KJ,

Morel J,

Alten R,

Zhu B,

Kristensen et al. compared 14 PsA drugs across five treatment classes, evaluating their real-world effectiveness over three months. Ixekizumab showed rapid effectiveness on joint disease activity and skin outcomes, performing better than IL-12/23i and IL-23i, and comparable to TNFi and JAKi. More patients with active psoriasis achieved minimal disease activity with Ixekizumab than other therapies.

Keywords:

February 2021

Le Baricitinib Inhibe la Progression des Lésions Articulaires Structurales Chez les Patients Atteints de Polyarthrite Rhumatoïde - Étude Approfondie

Arthritis Res Ther 2021;23(1):3.

Emery P,

Durez P,

MRI studies have shown that BARI reduces joint inflammation and damage in patients with moderate-to-severe active RA. This review summarises the effects of BARI on structural joint damage progression and the mechanisms underlying these effects, using MRI data from across the clinical trial program. Early preclinical animal models showed a significant reduction in joint inflammation, ankle width, and bone resorption. Efficacy and safety of BARI have been confirmed in an extensive programme, inclu...

Keywords:

September 2020

Évaluation de l'association des anticorps anti-CarbV et anti-MCV avec la réponse au traitement et la progression radiographique dans une population de patients PR traités soit par le méthotrexate soit par le baricitinib : analyses post-hoc de RA-BEGIN

Arthritis Res Ther. 2020;22(1):193

Bang H,

Autoantibodies associated with the onset of RA have gained attention in recent years as prognostic biomarkers. Though not used diagnostically, anti-CarbV (carbamylated vimentin) and anti-MCV (vimentin modified by citrullination) baseline titers are being investigated as predictors of treatment response. In this post-hoc analysis of data from the RA-BEGIN cohort of active RA patients, López-Romero and colleagues consider the potential predictive values of baseline anti-CarbV and anti-MCV titers r...